|
pharma market research - the original one-stop pharmaceutical information shop
PHARMA MARKET RESEARCH STUDIES
Global Biosimilars: A return to optimism?
Cardiac Rhythm Management Devices: World Market Outlook 2011-2021
Chinese Pharmaceutical Market 2012-2022
Biobanking for Medicine: Technology and Market 2012-2022
Point of Care Diagnostics: World Market Outlook 2012-2021
Generic Drugs: Global collaboration opportunities
Covidien Medical Device Company Intelligence Report
The Outlook for Pharmaceuticals in North East Asia
|
|
|
News Article
Published: March 2005
Sector: Press Release
|
SAN DIEGO, March 1 /PRNewswire/ -- MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange, today announced the enrollment of patients in a Phase II clinical study with MN-305, a novel anti-anxiety agent that was licensed in 2004 from Mitsubishi Pharma Corporation of Osaka, Japan. MN-305 is described as a serotonin type 1A receptor agonist, and based on preclinical and earlier clinical studies, appears to hold the potential for rapid onset of anti-anxiety effect combined with excellent tolerability.
Under the licensing agreement with Mitsubishi, MediciNova obtained exclusive worldwide rights, except for Japan, China, Taiwan, South Korea and other parts of Southeast Asia, to develop and commercialize MN-305. MediciNova has chosen to initiate the clinical development of MN-305 for generalized anxiety disorder, which, according to the National Institute of Mental Health, afflicts more than 4 million adult Americans.
"This study signals the beginning of a very ambitious clinical development undertaking for MediciNova during 2005," commented Richard Gammans, Ph.D., Executive Vice President, Clinical Research at MediciNova. "We plan to enroll 400 patients at 15 sites in the U.S. in this study with MN-305, and before the end of this year we hope to initiate four additional Phase II clinical studies with other compounds in the Company's portfolio, including potential new treatments for asthma, multiple sclerosis, interstitial cystitis, and premature labor."
This press release is provided in good-faith by Chiltern Magazine Services Ltd ("CMS") as a service to users. Whilst every care is taken in sourcing and preparing material included here, any error or incorrect content cannot form the basis for any legal action against the site-owner. Users are advised to check the accuracy of any statements before relying upon them. Likewise, any forward-looking statements made by the author of the press release should be treated as such.
For full details, please email keithw@cmsinfo.com
|
